TRMT2B Antibody

What is TRMT2B and why is it significant in mitochondrial research?

TRMT2B (TRM2 tRNA methyltransferase 2 homolog B) is a nuclear-encoded enzyme that catalyzes the formation of 5-methyluridine (m5U) in both mitochondrial tRNAs and rRNAs. Research has demonstrated that TRMT2B specifically targets U54 in mitochondrial tRNAs (including mt-tRNA Pro, mt-tRNA Asn, and mt-tRNA Gln) and U429 in 12S mitochondrial rRNA . The protein functions exclusively in mitochondria, where it plays a role in post-transcriptional modification of RNA species that form part of the epitranscriptome.

Unlike its paralog TRMT2A, which modifies cytosolic tRNAs, TRMT2B contains a mitochondrial targeting sequence and colocalizes with mitochondrial proteins such as TOM20 . The significance of TRMT2B lies in understanding fundamental mechanisms of RNA modification in mitochondria, although knockout studies suggest it is not essential for cell viability or mitochondrial function under standard conditions.

How should researchers optimize antigen retrieval when using TRMT2B antibodies for IHC applications?

Optimizing antigen retrieval is critical for successful TRMT2B detection in IHC applications. Based on experimental protocols, two distinct buffer systems have proven effective:

Primary recommendation: Use TE buffer at pH 9.0 for antigen retrieval. This alkaline environment has shown superior results in unmasking TRMT2B epitopes in formalin-fixed, paraffin-embedded (FFPE) tissues, particularly in human liver cancer and colon samples .

Alternative approach: If suboptimal results are obtained with TE buffer, citrate buffer at pH 6.0 can be used as an alternative retrieval solution . The difference in pH creates distinct unfolding patterns of fixed proteins that may better expose certain epitopes.

For experimental validation, it is advisable to perform a titration series with both retrieval methods on the same tissue type. The optimal protocol should demonstrate:

• Clear subcellular localization (primarily mitochondrial)

• Minimal background staining

• Reproducible signal intensity across multiple experiments

For IHC applications, dilution ranges between 1:20-1:200 are recommended, with optimal results typically observed in the 1:50-1:100 range .

What are the recommended positive controls for validating TRMT2B antibody specificity in Western blot applications?

When validating TRMT2B antibody specificity in Western blot applications, several well-characterized controls have been established:

Recommended positive controls:

• HepG2 cells (human liver cancer cell line) - Consistently shows strong TRMT2B expression with observed molecular weight of 50-56 kDa

• Human liver tissue lysate - Shows detectable TRMT2B expression

• Recombinant TRMT2B protein - When available, provides definitive confirmation of specificity

Negative controls for validation:

• TRMT2B knockout cell lines (e.g., HAP1 TRMT2B KO) - Should show absence of band at 50-56 kDa

• TRMT2B siRNA-treated samples - Should show significantly reduced band intensity

For Western blot applications, optimal dilution ranges are typically 1:500-1:1000, with proper optimization based on detection method and protein abundance . Observed molecular weight variations (50-56 kDa) are consistent with the calculated molecular weight of 56 kDa (504 amino acids) , with slight variations possibly due to post-translational modifications.

How can TRMT2B antibodies be employed to investigate mitochondrial RNA modification pathways in disease models?

TRMT2B antibodies can be strategically used to investigate the role of RNA modifications in disease models through several advanced methodological approaches:

Immunoprecipitation coupled with RNA analysis:
By using TRMT2B antibodies for RNA immunoprecipitation (RIP) followed by sequencing, researchers can identify the complete repertoire of TRMT2B RNA targets in disease states. This is particularly valuable since TRMT2B has been shown to modify both mt-tRNAs at position 54 and 12S rRNA at position U429 .

Proximity labeling approaches:
By coupling TRMT2B antibodies with proximity labeling techniques (BioID or APEX), researchers can identify proteins that interact with TRMT2B in the mitochondrial RNA modification landscape. This can reveal dysregulation in RNA modification pathways in disease states.

Dual immunofluorescence studies:
TRMT2B antibodies can be used in conjunction with antibodies against other mitochondrial proteins to investigate colocalization patterns in disease models. Studies have already established colocalization between TRMT2B and TOM20, confirming its mitochondrial localization .

Research has shown that while TRMT2B knockout does not produce obvious phenotypes under standard conditions, investigating its role under stress conditions (heat shock, oxidative stress) or in disease models may reveal context-dependent functions. For instance, the structural contribution of m5U54 modification may become significant under cellular stress conditions, as evidenced by electrophoretic mobility shifts observed in mt-tRNA LeuUUR in TRMT2B knockout cells .

What methodological approaches should be used to investigate TRMT2B's role in both tRNA and rRNA methylation simultaneously?

Investigating TRMT2B's dual role in tRNA and rRNA methylation requires integrated methodological approaches:

Recommended multi-modal analysis protocol:

• Hydrazine/aniline treatment followed by primer extension:
  This technique has been established as effective for detecting m5U modifications in both tRNAs and rRNAs by exploiting m5U's resistance to depyrimidination in the presence of hydrazine . The procedure should include:

  • Treatment of RNA with hydrazine followed by aniline

  • Reverse transcription with specific primers for target tRNAs and rRNAs

  • Analysis of stalling patterns at m5U positions (U54 in tRNAs, U429 in 12S rRNA)

  • Comparison between wild-type and TRMT2B-depleted samples

• Quantitative mass spectrometry analysis:
  For global assessment of m5U levels in different RNA species, mass spectrometry provides comprehensive quantification:

  • Separate extraction of small RNAs (tRNAs) and rRNAs

  • Enzymatic digestion to nucleosides

  • LC-MS/MS analysis to quantify m5U levels in different RNA fractions

  • Normalization to total uridine content

• Functional assessment in TRMT2B-depleted systems:
  To assess the biological significance of TRMT2B's dual activity:

  • Monitor aminoacylation levels of mt-tRNAs using acidic-PAGE

  • Assess mitoribosome assembly via sucrose gradient analysis

  • Examine mitochondrial translation using pulse labeling with [35S]-methionine

Research has demonstrated that TRMT2B knockout cells show no significant differences in aminoacylation levels of m5U54-containing mt-tRNAs, suggesting the modification is not critical for this process under standard conditions . Likewise, the stability of mitoribosomal subunits appears unaffected by loss of TRMT2B-mediated m5U429 in 12S rRNA .

How should researchers address potential cross-reactivity issues when using TRMT2B antibodies in mitochondrial studies?

Cross-reactivity is a significant concern when using TRMT2B antibodies, particularly due to potential recognition of the paralog TRMT2A or other methyltransferases. Here's a systematic approach to address and mitigate cross-reactivity:

Validation strategies to confirm specificity:

• Comparative analysis with TRMT2B knockout models:

  • Use TRMT2B knockout cell lines (e.g., HAP1 TRMT2B KO) as negative controls

  • Confirm complete absence of signal in knockout samples

  • Be alert to residual signals that may indicate cross-reactivity with TRMT2A

• Subcellular fractionation validation:

  • Perform subcellular fractionation to separate mitochondrial and cytosolic fractions

  • Authentic TRMT2B signal should be enriched in mitochondrial fractions

  • TRMT2A signal should predominate in cytosolic fractions

  • Use established markers (TOM20 for mitochondria, tubulin for cytosol) to confirm fraction purity

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide

  • True TRMT2B signal should be abolished in peptide-blocked samples

  • Persistent signals suggest non-specific binding

Mitigation strategies for research applications:

• Use antibodies raised against regions with minimal homology between TRMT2A and TRMT2B

• When possible, confirm key findings with multiple TRMT2B antibodies targeting different epitopes

• Consider using epitope-tagged TRMT2B expression systems for unambiguous detection

Research suggests that TRMT2B has a mitochondrial targeting sequence that is absent in TRMT2A , which can be leveraged to confirm specificity of antibody binding.

What factors account for variability in observed molecular weights of TRMT2B in Western blot analyses across different experimental systems?

Several research groups have reported variations in the observed molecular weight of TRMT2B in Western blot analyses, typically in the range of 50-56 kDa . Understanding these variations is essential for proper data interpretation:

Factors contributing to molecular weight variability:

• Post-translational modifications:

  • Phosphorylation sites have been identified in TRMT2B that can add approximately 1-2 kDa

  • Other potential modifications include methylation, acetylation, or SUMOylation

• Mitochondrial targeting sequence processing:

  • TRMT2B contains an N-terminal mitochondrial targeting sequence (MTS)

  • Upon import into mitochondria, this sequence is typically cleaved by mitochondrial processing peptidase

  • The processed form would appear smaller (approximately 4-6 kDa less) than the full-length protein

• Alternative splicing:

  • Multiple transcript variants of TRMT2B have been identified

  • Expression of different isoforms can lead to size variations

• Experimental conditions affecting migration:

  • SDS-PAGE percentage significantly impacts observed molecular weight

  • Reducing vs. non-reducing conditions can alter protein conformation and migration

  • Buffer composition during sample preparation can affect denaturation efficiency

Recommended controls for accurate interpretation:

• Include recombinant TRMT2B protein of known molecular weight as a standard

• Run samples from multiple cell types in parallel to assess tissue-specific variations

• Document specific SDS-PAGE conditions (percentage, buffer system) to facilitate comparison across studies

Research has shown that the calculated molecular weight of TRMT2B is 56 kDa (504 amino acids) , but observed values in Western blot applications typically range from 50-56 kDa, with the variability attributed to the factors outlined above.

How can TRMT2B antibodies be utilized to investigate the evolutionary conservation of mitochondrial RNA modification mechanisms?

TRMT2B antibodies offer valuable tools for comparative studies exploring the evolutionary conservation of mitochondrial RNA modification systems across species:

Methodological approach for cross-species investigations:

• Antibody cross-reactivity assessment:

  • Test existing TRMT2B antibodies against samples from diverse species

  • Focus on conserved epitopes based on sequence alignment analysis

  • Establish species-specific dilution optimization protocols

• Comparative immunolocalization studies:

  • Use confocal microscopy with TRMT2B antibodies across species

  • Compare subcellular localization patterns in relation to mitochondrial networks

  • Quantify colocalization coefficients with established mitochondrial markers

• Investigation of bovine-specific TRMT2B inactivation:
  Research has revealed a fascinating evolutionary phenomenon where the Bovinae subfamily has a naturally occurring substitution of the catalytic cysteine to tyrosine in TRMT2B, rendering it catalytically inactive . This explains the observed absence of m5U54 in bovine mt-tRNAs while it remains present in cytosolic tRNAs (modified by TRMT2A) .

  This natural "knockout" model can be investigated using:

  • Comparative immunoprecipitation studies between bovine and human TRMT2B

  • Analysis of potential alternative functions of catalytically inactive bovine TRMT2B

  • Investigation of compensatory mechanisms in bovine mitochondria

Sequence alignment analyses show the SAM binding site is highly conserved in TRMT2B across species, while there are dramatic divergences in other regions of the active site in some species, particularly in the Bovinae subfamily . This natural variation provides a unique opportunity to study the functional evolution of RNA modification systems.

What methodological considerations should be addressed when using TRMT2B antibodies to investigate potential non-canonical functions beyond RNA methylation?

Recent research suggests TRMT2B may have functions beyond its established role in RNA methylation, similar to its yeast homolog Trm2, which has been proposed to have chaperone-like functions and DNA repair activities . Investigating these potential non-canonical functions requires careful methodological considerations:

Experimental strategies for non-canonical function investigation:

• Catalytically inactive TRMT2B studies:

  • Design point mutations in the SAM-binding domain to create catalytically inactive TRMT2B

  • Use TRMT2B antibodies to immunoprecipitate both wild-type and catalytically inactive forms

  • Compare interactomes and associated RNAs to identify methylation-independent interactions

  • Leverage the natural bovine TRMT2B "inactive" variant as a model system

• DNA damage response investigation:

  • Induce DNA damage using standardized methods (UV irradiation, chemical agents)

  • Use TRMT2B antibodies for chromatin immunoprecipitation (ChIP) to assess DNA association

  • Perform immunofluorescence studies to monitor potential nuclear relocalization under stress

  • Compare results between control and TRMT2B-depleted cells

• Stress condition-specific analyses:

  • Subject cells to various stress conditions (heat shock, oxidative stress, ER stress)

  • Analyze potential changes in TRMT2B localization, interaction partners, and post-translational modifications

  • Compare cellular responses between wild-type and TRMT2B-knockout cells under stress conditions

While current research shows no obvious phenotype from TRMT2B knockout under standard conditions , its potential non-canonical functions may become apparent only under specific cellular stresses or in particular tissue contexts, similar to observations in yeast where Trm2 deletion induced lethality only in combination with specific tRNA mutations .

What modifications to standard protocols are necessary when using TRMT2B antibodies in neurological tissue samples?

Neurological tissue samples present unique challenges for TRMT2B immunodetection due to their high lipid content, dense cellular architecture, and elevated mitochondrial abundance. Protocol optimization should address these tissue-specific considerations:

Recommended protocol adjustments for neurological tissues:

• Sample preparation modifications:

  • Extend fixation time for FFPE samples to 24-48 hours to ensure complete penetration

  • For frozen sections, use thicker sections (12-16 μm) to preserve tissue integrity

  • Consider specialized fixatives for brain tissue (e.g., zinc-based fixatives) that better preserve protein epitopes

• Antigen retrieval optimization:

  • Extend heat-induced epitope retrieval (HIER) time to 25-30 minutes

  • Use higher temperature (97-99°C) for more efficient unmasking

  • Consider dual retrieval methods (heat followed by enzymatic treatment) for heavily fixed samples

• Signal detection and background reduction:

  • Implement extended blocking steps (2-3 hours) with 5-10% normal serum plus 0.1-0.3% Triton X-100

  • Use longer primary antibody incubation (overnight at 4°C or 48 hours for thick sections)

  • Include lipid-clearing steps (such as Sudan Black B treatment) to reduce lipofuscin autofluorescence

  • Consider tyramide signal amplification for enhanced detection in specimens with low TRMT2B expression

• Counterstaining and colocalization strategies:

  • Pair with mitochondrial markers optimized for neuronal tissues (e.g., COXIV, Porin/VDAC)

  • Use neuronal markers (NeuN, MAP2) or glial markers (GFAP, Iba1) for cell-type specific analysis

  • Implement spectral unmixing for accurate separation of signals in multi-label experiments

While standard dilution ranges for TRMT2B antibodies (1:20-1:200 for IHC) can serve as starting points, neurological tissues typically require optimization toward the more concentrated end of this range (approximately 1:20-1:50) due to complex fixation chemistry and tissue density.

How can researchers effectively use TRMT2B antibodies to analyze patient-derived samples in clinical research settings?

Using TRMT2B antibodies for clinical research requires rigorous standardization and quality control to ensure reproducibility and meaningful data interpretation across patient cohorts:

Standardization protocol for clinical sample analysis:

• Pre-analytical variables control:

  • Implement standardized collection protocols with defined cold ischemia time (<30 minutes)

  • Use consistent fixation parameters (10% neutral buffered formalin, 24-48 hours)

  • Document patient variables (age, sex, medication status) that may affect mitochondrial dynamics

  • Include age-matched controls processed in parallel with patient samples

• Batch processing and controls:

  • Process test and control samples in the same experimental batch

  • Include tissue microarrays with known TRMT2B expression levels as inter-experimental controls

  • Implement digital pathology quantification for objective assessment

  • Use multi-site validation if integrating samples from different clinical centers

• Validation in patient-derived cell models:

  • Establish fibroblast or lymphoblast cultures from patients for complementary in vitro studies

  • Use multiple methodologies (Western blot, immunofluorescence) to cross-validate findings

  • Correlate antibody-based detection with functional readouts (RNA modification levels)

• Specialized protocols for biopsy materials:
  For limited clinical specimens such as needle biopsies:

  • Optimize protocols for small sample volumes (using carrier proteins if necessary)

  • Implement whole-slide scanning and image analysis for comprehensive tissue assessment

  • Consider signal amplification methods (e.g., polymer detection systems) to maximize sensitivity

Interpretation framework for clinical research:

• Establish baseline ranges for TRMT2B expression in normal tissues using public repositories

• Determine if alterations reflect changes in expression or localization

• Correlate findings with mitochondrial markers to assess potential dysfunction

• Interpret changes in the context of tissue-specific mitochondrial content